GlaxoSmithKline's Digital Strategy and Transformation

GLAXOSMITHKLINE DIGITAL STRATEGY AND TRANSFORMATION
By (Student's Name)
Course
Professor's Name
University
City and State
Due Date
The largest 350 firms on the London Stock Exchange comprise the FTSE 350 index. These businesses are regarded as the UK's most valuable and significant businesses. I have selected the FTSE 100 index-listed business GSK (GlaxoSmithKline) for this study. GSK develops and delivers drugs, vaccines, as well as consumer healthcare products geared at impacting population health outcomes. The firm's operations spread across the value chain spanning from recognizing, researching, developing, and assessing ground-breaking innovations to regulatory approval, commercialization, and manufacturing. The company is currently harnessing the possibilities presented by digital tools and capabilities, including machine learning (ML), artificial intelligence (AI), as well as deep learning (DL) to augment medication discovery as well as a development process to reduce timescales and operational costs. The history of the global pharmaceutical business, GSK, dates back to 1715. The corporation now employs over 92,000 individuals and operates in over 150 nations. Central to the company's success include human resources, manufacturing, science, technology, intellectual property, commercialization, and regulation experts’ capabilities. This paper evaluates GSK's digital strategy and transformation based on justification and rationale for the choice of the company, digital disruptions within the firm's industry, digital technologies and innovation employed, and the emerging technologies likely to impact the future of the selected company. The paper also includes recommendations for the company to augment its digital strategy and transformation endeavors.
Justification and Rationale
Due to the considerable digital disruption the pharmaceutical business is experiencing, GSK will be the subject of this analysis. Companies in this industry are pressured to remain flexible and creative due to the emergence of new technology and shifting client expectations. GSK's approach to digital disruption is particularly interesting as a significant participant in the sector. Enhancing research and development is among the justification and rationale at GSK. GSK has used digital technologies to speed up the drug discovery and growth processes. By utilizing machine learning and artificial intelligence (AI), GSK is able to analyze massive amounts of data and determine potential drug targets with greater speed and accuracy, which can lead to more effective research and development and, eventually, faster accessibility for patients to novel treatments. The digital revolution objectives also justified by the need to augment patient outcomes. In order to create more individualized treatments and services, GSK can benefit from using digital technologies better to comprehend the requirements and preferences of its patients. For instance, GSK has created digital health solutions like wearables and smartphone apps to assist patients in better managing their diseases and complying with treatment plans (GSK Annual Report, 2022). Better health results and increased patient satisfaction may result from this.
Evaluation
Dig...